Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- JPMA Chief Lauds MHLW’s Comprehensive Strategy, Says It Will Support Industry as a Whole
September 7, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Ryukaikon’s New Proposal “Will Greatly Promote the Improvement of Distribution”: JPWA President
September 2, 2015
- Cost-Effective Assessment Must Not Delay Patient Access: PhRMA’s HTA Chief
September 1, 2015
- JMA, JAMS Issue Guidelines for Dealing with Symptoms Following HPV Vaccination; Use of Word “Psychogenic” Should Be Avoided in Pain Diagnoses
August 21, 2015
- Compensation for Injured Subjects an “Agreement,” Not a “Benefit”: Ihoken Revised Guidelines
August 20, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 1
August 20, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- Govt Leadership Needed to Promote Industry Reorganization, Strengthen Competitiveness: Former JPMA President Aoki
August 17, 2015
- Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
August 14, 2015
- Drug Pricing Tomorrow: Full Interview with JPA Executive Director Abe
August 13, 2015
- Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags
August 10, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- JPMA Establishes “Global Health Taskforce” in IP Committee
August 5, 2015
- “All-Japan” System Needed to Contend with Top Global Drug Makers: JPMA R&D Head
August 3, 2015
- Drug Pricing Tomorrow: JPA’s Abe Eyes Longer-Term Trial for Key Pricing Premium
July 28, 2015
- No. of Sales Reps Decreases by over 1,000 in FY2014
July 28, 2015
- Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
- Hodanren Demands Abolishment of Innovation Premium
July 17, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…